Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng(National Taiwan University Hospital), Yoon‐Koo Kang(Asan Medical Center), Zhendong Chen(Anhui Medical University), Chao-Jung Tsao(Chi Mei Medical Center), Shukui Qin(81th Hospital of PLA), Jun Suk Kim(Korea University Medical Center), Rongcheng Luo(Nanfang Hospital), Jifeng Feng(Jiangsu Cancer Hospital), Sheng‐Long Ye(Sun Yat-sen University), Tsai‐Sheng Yang(Chang Gung Memorial Hospital), Jianming Xu(Academy of Military Medical Sciences), Yan Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Houjie Liang(Army Medical University), Jiwei Liu(Dalian Medical University), Jiejun Wang(Shanghai Changzheng Hospital), Won Young Tak(Kyungpook National University Hospital), Hongming Pan(Sir Run Run Shaw Hospital), K. Burock(Bayer (Germany)), Jessie Zou(Bayer (China)), D. Voliotis(Bayer (United States)), Zhongzhen Guan(Sun Yat-sen University)
The Lancet Oncology
December 18, 2008
Cited by 5,833

Abstract


Related Papers

No related papers found

Powered by citation graph analysis